A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
ALX Oncology Inc.
Pfizer
Aurigene Discovery Technologies Limited
Aurigene Discovery Technologies Limited
Pheon Therapeutics
Eli Lilly and Company
University of Pittsburgh
Kestrel Therapeutics, Inc.
National Cancer Institute (NCI)
Revolution Medicines, Inc.
Memorial Sloan Kettering Cancer Center
Seagen Inc.
Turning Point Therapeutics, Inc.
Alterome Therapeutics, Inc.
Orano Med LLC
RasCal Therapeutics, Inc.
Pfizer
Xencor, Inc.
City of Hope Medical Center
University Hospital, Clermont-Ferrand
University of Pennsylvania
Duke University
A2 Biotherapeutics Inc.
Mirati Therapeutics Inc.
Arvinas Inc.
Zhejiang University
National Institutes of Health Clinical Center (CC)
MBrace Therapeutics
Ulsan University Hospital
New Phase Ltd.
Revolution Medicines, Inc.
University of Colorado, Denver
Roswell Park Cancer Institute
Pheon Therapeutics
City of Hope Medical Center
Eli Lilly and Company
Novartis
Var2 Pharmaceuticals
University of Salamanca
Takeda
NantCell, Inc.
City of Hope Medical Center
AstraZeneca
Revolution Medicines, Inc.
Tempus AI
Virginia Commonwealth University
University of Calgary
Chongqing Precision Biotech Co., Ltd
HUYABIO International, LLC.